{"nctId":"NCT00548340","briefTitle":"VEC-162 Study in Adult Patients With Primary Insomnia","startDateStruct":{"date":"2007-11"},"conditions":["Primary Insomnia"],"count":322,"armGroups":[{"label":"VEC-162 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: VEC-162 20 mg"]},{"label":"VEC-162 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: VEC-162 50 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"VEC-162 20 mg","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"VEC-162 50 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females with a diagnosis of primary insomnia as defined in DSM-IV.\n* Habitual bedtime between 9:00 pm and 1:00 am.\n* No history or evidence of restless leg syndrome or periodic limb movement disorder or sleep apnea.\n* Patients must sign a written consent form.\n\nExclusion Criteria:\n\n* History of drug or alcohol abuse as defined in DSM-IV.\n* History of psychiatric disorders, including Major Depressive Disorder, Generalized Anxiety Disorder and delirium.\n* History of chronic obstructive pulmonary disease (COPD), seizures, sleep apnea, narcolepsy, circadian-rhythm sleep disorder, parasomnia or any sleep disorder other than chronic insomnia.\n* Recent history of shift work or jet lag.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Change From Baseline - Latency to Persistent Sleep (LPS)","description":"Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point at which 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline and the average of nights 1 and 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":"2.965"},{"groupId":"OG001","value":"46.4","spread":"2.954"},{"groupId":"OG002","value":"28.3","spread":"3.020"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)","description":"Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 1 and 8. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 1 and 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"4.349"},{"groupId":"OG001","value":"14.1","spread":"4.329"},{"groupId":"OG002","value":"11.7","spread":"4.569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":"4.794"},{"groupId":"OG001","value":"52.0","spread":"4.775"},{"groupId":"OG002","value":"39.9","spread":"4.882"}]}]}]},{"type":"POST_HOC","title":"Average Change From Baseline - Latency to Persistent Sleep (LPS)","description":"Average latency to persistent sleep is defined as the length of time elapsed between lights off and onset of persistent sleep (defined as the point 10 minutes of uninterrupted sleep has begun as determined by PSG) between Baseline, and the average of nights 22 and 29.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":"3.309"},{"groupId":"OG001","value":"45.1","spread":"3.292"},{"groupId":"OG002","value":"33.9","spread":"3.338"}]}]}]},{"type":"POST_HOC","title":"Average Change From Baseline - Wake After Sleep Onset (WASO) and Total Sleep Time (TST)","description":"Average wake after sleep onset was defined as the time spent awake between onset of sleep (latency to non-awake) and lights-on, as determined by PSG between Baseline, and the average of nights 22 and 29. Total sleep time (TST) was defined as the time spent sleeping between lights-out and lights-on, i.e., full night between Baseline, and the average of nights 22 and 29.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":"4.139"},{"groupId":"OG001","value":"10.2","spread":"4.184"},{"groupId":"OG002","value":"20.3","spread":"4.381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":"4.821"},{"groupId":"OG001","value":"48.6","spread":"4.802"},{"groupId":"OG002","value":"47.4","spread":"4.882"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":109},"commonTop":["Headache","Nasopharyngitis","Blood Creatine Phosphokinase Increased","Urinary Tract Infection"]}}}